Skip to content
Screener

Neuropace, Inc. NPCE Total Operating Expenses

Total Operating Expenses at other companies

Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$60.81M+106%
CVRx, Inc. logo
CVRx, Inc.CVRX
$26.75M+3.6%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$123.16M+30.7%
Neuronetics logo
NeuroneticsSTIM
$22.72M-12.0%
ITG
Integer HoldingsITGR
$77.73M+9.8%
VAN
Vivani MedicalVANI
$6.82M+4.0%

Other financials

Income statement

See full
Revenue$22.8M+17.1%
Gross profit$18.9M+16.6%
Operating income-$5.1M+37.2%
Net income-$6.2M+28.3%
EPS (diluted)-$0.18+30.8%

Balance sheet

See full
Cash & equivalents$12.8M-44.4%
Total debt$69.9M-2.2%
Total equity$11.9M-38.9%
Total assets$97.0M-8.6%

Cash flow

See full
Operating cash flow-$3.9M-87.1%
CapEx$125.0K-25.6%
Free cash flow-$4.0M-78.7%

Valuation

See full
Market cap$507.31M+74.0%
Enterprise value$564.47M+66.0%
P/S5.1×+1.7×

Profitability

See full
Gross margin79.6%+2.6pp
Operating margin-15.3%-4.3pp
Net margin-19.3%-5.2pp
FCF margin-12.2%-3.3pp

Returns & leverage

See full
Return on equity-122.1%-28.9pp
Debt / equity5.9×+2.2×
Current ratio4.9×-0.5×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Neuropace, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:33 PM EDT
Fiscal quarter
Q4 FY2030
Calendar quarter
Q4 2030
Accession
0001528287-26-000030
(in thousands, except for share and per share amounts)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Sales and marketing12,12411,48923,70721,894
Research and development6,8986,84514,08714,285
General and administrative5,0276,0689,87110,114
Total operating expenses24,04924,40247,66546,293
Loss from continuing operations(5,143)(8,189)(10,748)(14,949)
Interest income5237181,0881,511
Interest expense(1,539)(2,059)(3,060)(4,212)
Other income (expense), net(41)(486)(206)(568)

Item 1. Financial Statements (Unaudited)

FAQ

What is Neuropace, Inc.'s total operating expenses?
Neuropace, Inc. (NPCE) reported total operating expenses of $24.05M in Q2 2026.
How has Neuropace, Inc.'s total operating expenses changed year-over-year?
Neuropace, Inc.'s total operating expenses decreased by 1.4% year-over-year, from $24.4M to $24.05M.
What is the long-term trend for Neuropace, Inc.'s total operating expenses?
Over 4 years (2021 to 2025), Neuropace, Inc.'s total operating expenses has grown at a 12.9% compound annual growth rate (CAGR), from $57.17M to $93M.
What does total operating expenses mean?
The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.

Ask your AI about Neuropace, Inc.'s total operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude